Kidney involvement in systemic lupus erythematosus (SLE, lupus) is an important predictor of and contributor to morbidity and mortality from lupus. The approach to treatment for lupus nephritis is that of an induction phase of therapy (with cyclophosphamide vs mycophenolate mofetil) followed by long-term maintenance therapy. However, the optimal agent for chronic immunosuppression to prevent relapse or worsening of renal SLE is unknown.
Abatacept is a selective T-cell co-stimulation modulator that has demonstrated efficacy for the treatment of rheumatoid arthritis in patients who have failed treatment with methotrexate. Until recently, abatacept was only available as a monthly intravenous infusion. In August 2011, the FDA approved the use of subcutaneous abatacept for the treatment of moderate to severe rheumatoid […]
The development of antidrug antibodies to biologic therapies, notably drugs that consist of monoclonal antibodies (such as adalimumab and infliximab) has been reported in patients with rheumatoid arthritis. However, the clinical significance of these antidrug antibodies in the long-term follow up of RA patients is unknown.
Vaccinations are a critical component of RA clinical management, and their importance in preventing infection cannot be stressed enough. The majority of patients with RA are on immunosuppressive treatment, and a data driven approach to vaccinations in this high-risk population is essential.
Belimumab is a fully human IgG1λ antibody. It binds to the soluble cytokine, B-lymphocyte stimulator (BLyS) inhibiting its action. BLyS is important for the survival of B lymphocytes, but in patients with systemic lupus erythematosus (SLE) it is overexpressed.